Shanghai Junshi Biosciences Co Revenue
Biotechnology Research • 
Pudong, Shanghai, China • 201-500 Employees
Shanghai Junshi Biosciences Co revenue & valuation
| Annual revenue | $212,000,000 |
| Revenue per employee | $1,000,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $678,200,000 |
| Total funding | No funding |
Key Contacts at Shanghai Junshi Biosciences Co
Di Zhu
Senior Director, Clinical Data Management
Jing Tong
Senior Director
Yanbei Huang
Clinical Project Director
Anna Wang
Senior Director Of Hr & Admin
Joanna Xie
Associate Director Of Business Development
Xiaoli Wu
Associate Director, Data Analytics
Yanming An Ph D.. Rac
Senior Director Of Regulatory Affairs
Charlin Yaling
Associate Medical Director
Bai Shi
Senior Quality Director
Harry Chen
Associate Medical Director
Company overview
| Headquarters | 15F, Building 7, No.6, Lane 100, Pingjiaqiao Road, Pudong New Area, Shanghai, 200126, CN |
| Phone number | +862120248288 |
| Website | |
| SIC | 283 |
| Founded | 2012 |
| Employees | 201-500 |
| Socials |
Shanghai Junshi Biosciences Co Email Formats
Shanghai Junshi Biosciences Co uses 2 email formats. The most common is {first name}_{last name} (e.g., john_doe@junshipharma.com), used 96.3% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}_{last name} | john_doe@junshipharma.com | 96.3% |
{first name}.{last name} | john.doe@junshipharma.com | 3.7% |
About Shanghai Junshi Biosciences Co
Junshi BioPharma is an innovation-driven biopharmaceutical company which is dedicated to the discovery and development of innovative drugs and their clinical research and commercialization on a global scale. Our mission is to provide patients with treatment options that work better and cost less. Based on the core platform technology of protein engineering, Junshi stands at the frontier of R&D of macromolecular drugs. With distinguished capability of innovative drug discovery, advanced biotechnological R&D, large-scale production capacity on the full industry chain and rapidly expanding drug candidate portfolio of tremendous market potential, Junshi has a leading edge in the PRC in the emerging field of immuno-oncology and for the treatment of autoimmune and metabolic diseases. Junshi is the first PRC company filing IND application and NDA application to the NMPA for anti-PD-1 monoclonal antibody, and also the first PRC company to receive IND approvals from the NMPA for anti-PCSK9 monoclonal antibody and anti-BLyS monoclonal antibody. Our vision is to become a pioneer in the area of translational medicine by developing first-in-class and best-in-class drugs through original innovation. With enrichment of our product pipelines and exploration of drug combination therapies, Junshi expanded its innovation to the R&D of more types of drugs, including small molecule drugs and antibody drug conjugates (or ADCs), as well as to the exploration of the next-generation innovative therapies for cancer and autoimmune diseases.
Employees by Management Level
Total employees: 201-500
Seniority
Employees
Employees by Department
Shanghai Junshi Biosciences Co has 41 employees across 11 departments.
Departments
Number of employees
Funding Data
Shanghai Junshi Biosciences Co has never raised funding before.
Shanghai Junshi Biosciences Co Tech Stack
Discover the technologies and tools that power Shanghai Junshi Biosciences Co's digital infrastructure, from frameworks to analytics platforms.
Web servers
UI frameworks
JavaScript libraries
Databases
Photo galleries
Programming languages
Miscellaneous
Blogs
JavaScript libraries
JavaScript libraries
Translation
UI frameworks
Switzerland
New Zealand
Saudi Arabia
CanadaFrequently asked questions
4.8
40,000 users
